Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab + trastuzumab for trastuzumab-resistant advanced HER2-positive breast cancer
ACTRN12617001325392Phase 2Completed
- Sponsor
- Breast Cancer Trials
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tremelimumab, durvalumab and trastuzumab in breast cancer (3 cohorts), sponsored by Breast Cancer Trials. Primary endpoints: 12-month progression-free survival rate in 75 mg tremelimumab ER-positive and ER-negative cohorts and Objective response rate in single 300 mg tremelimumab priming-dose cohort. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12617001325392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001325392.